Christopher J. Gibson

机构：Merck & Co., Inc., Rahway, NJ, USA (United States), Dana-Farber Cancer Institute · ORCID：0000-0002-3700-5310

发表论文 261 篇 · 总被引 13223 次 · h-index 45

代表论文

• AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial (2024 · Blood · 被引 10)
• CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial (2026 · Blood Advances · 被引 7)
• Human plasma proteomic profile of clonal hematopoiesis (2025 · Nature Communications · 被引 7)
• Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia (2024 · Blood Advances · 被引 7)
• Somatic mutations in STAG2 are associated with separated megakaryocyte nuclear lobes in myelodysplastic syndromes (2025 · Blood Advances · 被引 2)
• Induction of Graft-Versus-Leukemia Effect with Treg-Depleted DLI Plus Ipilimumab for Myeloid Disease Relapse after HLA-Matched Transplant (2024 · Blood · 被引 2)